Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

Exclusion Criteria

• •Underlying conditions other than psoriasis that, in the opinion of the investigator, currently cause or influence pruritus of the overall skin
• •Current or past history of hypercalcemia, Vitamin D toxicity, severe renal insufficiency, or severe hepatic disorders
• •Thyroid abnormalities that, in the opinion of the investigator, are clinically relevant and may affect assessments
• •Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis
• •Subjects with a clinical diagnosis of bacterial infection of the skin
• •Subjects who have previously failed treatment with or failed to tolerate treatment with calcipotriene
• •Known hypersensitivity to SNA-120 (pegcantratinib), calcipotriene, the study treatment excipients, and /or polyethylene glycol (PEG), or a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation
• •Currently enrolled in an investigational drug or device study or has used an investigational drug or an investigational device treatment within 30 days or 5 half-lives of investigational drug (whichever is longer) of baseline
• •Women who are pregnant or lactating, or are planning to become pregnant during the study
• •Subjects previously participating in any SNA-120 (and/or CT327 or pegcantratinib) clinical studies